Merck’s Enlicitide: Breakthrough Oral Pill Dramatically Lowers Cholesterol New Orleans, LA – A groundbreaking new oral medication developed by Merck has demonstrated a remarkable ability to lower LDL cholesterol – often referred to as “bad” cholesterol – in patients already undergoing statin therapy. Presented Saturday at a major cardiology conference, late-stage trial results reveal that … Read more
Gene Editing for Cholesterol: The Dawn of ‘One-and-Done’ Cardiovascular Care Nearly 39% of U.S. adults aged 20 or older have high cholesterol – a silent killer contributing to heart disease, stroke, and countless other health complications. For decades, management has relied on lifelong medication and lifestyle changes. But what if a single treatment could permanently … Read more
Repatha Injection Significantly Reduces Cardiovascular Risk in High-Risk Patients New Orleans, LA – A groundbreaking study presented at the American Heart Association’s scientific sessions reveals that Repatha, a cholesterol-lowering injection, substantially reduces the risk of major cardiovascular events in individuals already at high risk but who have not yet experienced a heart attack or stroke. … Read more
Trump Administration’s Drug Price Deals: Are Savings as Promised? WASHINGTON – President Trump’s recent announcement of agreements to lower the cost of popular weight-loss medications, including Wegovy and Zepbound, was met with a bold claim: “You will pay the lowest price anywhere in the world.” However, emerging analysis suggests that state Medicaid programs may already … Read more
This is the online version of a report on healthcare financial updates. A significant shift in Medicare payment policies is poised to reshape the financial landscape for physicians in 2026. Late Friday, the Centers for Medicare & Medicaid Services (CMS) finalized its decision to implement a 2.5% reduction in payments for a wide range of … Read more
Pfizer Sues Novo Nordisk in Escalating Battle for Metsera In a dramatic turn of events, Pfizer initiated legal action against Novo Nordisk and Metsera on Friday, intensifying the competition to acquire the obesity-focused biotechnology firm. The lawsuit comes just one day after Novo Nordisk launched a counter-offer, challenging Pfizer’s previously agreed-upon $4.9 billion deal. The … Read more
Cigna Stock Plummets as Rebate-Free Pharmacy Model Threatens Profits New York, NY – Shares of Cigna Group (CI) experienced a dramatic sell-off on Thursday, tumbling over 15% in mid-morning trading following the company’s announcement of a significant shift in its pharmacy benefit management (PBM) strategy. The decline was triggered by revelations that eliminating pharmacy rebates, … Read more
FDA Moves to Accelerate Biosimilar Approvals, Potentially Lowering Drug Costs WASHINGTON – In a significant move aimed at increasing access to affordable medications, the Trump administration unveiled a draft framework Wednesday designed to expedite the approval process for biosimilar drugs. These “copycat” versions of complex biologic medications hold the promise of substantially reducing healthcare costs … Read more
Moderna’s CMV Vaccine Faces Setback in Late-Stage Trial Cambridge, Massachusetts – Moderna experienced a significant hurdle Wednesday as its experimental vaccine designed to prevent cytomegalovirus (CMV) infection failed to demonstrate efficacy in a Phase 3 clinical trial. This outcome represents a substantial setback for the biotechnology firm, particularly as it navigates increased scrutiny from investors … Read more
Washington D.C. – A recent analysis by the Congressional Budget Office (CBO) reveals the “One Big Beautiful Bill Act” is projected to cost taxpayers $8.8 billion over the next decade – a significant increase from initial estimates of $4.9 billion. The revised forecast stems from provisions within the legislation that exempt or delay Medicare price … Read more